CN114032294B - Radiation biological dose estimation method based on miRNA in peripheral blood plasma - Google Patents
Radiation biological dose estimation method based on miRNA in peripheral blood plasma Download PDFInfo
- Publication number
- CN114032294B CN114032294B CN202111636407.XA CN202111636407A CN114032294B CN 114032294 B CN114032294 B CN 114032294B CN 202111636407 A CN202111636407 A CN 202111636407A CN 114032294 B CN114032294 B CN 114032294B
- Authority
- CN
- China
- Prior art keywords
- mir
- mirna
- dose
- peripheral blood
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108091070501 miRNA Proteins 0.000 title claims abstract description 40
- 239000002679 microRNA Substances 0.000 title claims abstract description 36
- 230000005855 radiation Effects 0.000 title claims abstract description 31
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 22
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 22
- 210000002381 plasma Anatomy 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title abstract description 25
- 230000014509 gene expression Effects 0.000 claims abstract description 27
- 238000001514 detection method Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000012163 sequencing technique Methods 0.000 claims description 4
- 230000005251 gamma ray Effects 0.000 claims description 2
- 108091027034 miR-148a stem-loop Proteins 0.000 claims 1
- 108091044682 miR-184 stem-loop Proteins 0.000 claims 1
- 108091039438 miR-184-1 stem-loop Proteins 0.000 claims 1
- 108091059199 miR-200a stem-loop Proteins 0.000 claims 1
- 108091065218 miR-218-1 stem-loop Proteins 0.000 claims 1
- 108091054980 miR-218-2 stem-loop Proteins 0.000 claims 1
- 108091065376 miR-375 stem-loop Proteins 0.000 claims 1
- 108091031438 miR-375-3 stem-loop Proteins 0.000 claims 1
- 108091066335 Mus musculus miR-148a stem-loop Proteins 0.000 abstract description 4
- 230000003828 downregulation Effects 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 108091028466 miR-130b stem-loop Proteins 0.000 description 1
- 108091026034 miR-130b-1 stem-loop Proteins 0.000 description 1
- 108091090860 miR-150 stem-loop Proteins 0.000 description 1
- 108091055145 miR-342 stem-loop Proteins 0.000 description 1
- 108091037240 miR-423 stem-loop Proteins 0.000 description 1
- 108091061799 miR-676 stem-loop Proteins 0.000 description 1
- 108091092393 miR-676-1 stem-loop Proteins 0.000 description 1
- 108091046557 miR-676-2 stem-loop Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000012785 packaging film Substances 0.000 description 1
- 229920006280 packaging film Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001950 radioprotection Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention provides a radiation biological dose estimation method based on miRNA in peripheral blood plasma. The method mainly detects the expression quantity of the mmu-miR-148a-3p, the mmi-miR-184-3 p, the mmi-miR-200 a-5p, the mmi-miR-218-5 p and the mmi-miR-375-3 p in the peripheral blood plasma of the organism after being irradiated, and substitutes the expression quantity into a dose-effect function relation, so that the irradiation quantity can be calculated. The method is simple in operation, convenient, quick and objective.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a radiation biological dose estimation method based on miRNA in peripheral blood plasma.
Background
Under the condition that nuclear reactor accidents and nuclear weapon explosions occur in a nuclear power ship, people can generate acute radiation diseases with different degrees after being irradiated by ionizing radiation with different doses, and the severity of the acute radiation diseases and the parting graduation of the acute radiation diseases are closely related to irradiated doses. Therefore, the rapid and accurate assessment of the irradiated dose of personnel has important guiding significance for scientific judgment of the severity of the acute radiation disease and clinical indexing and stage treatment of the acute radiation disease.
There are three methods for estimating the dose of ionizing radiation: physical, biological and clinical, but because physical dosimeters can only reflect local dose, there are individual differences in the response of the staff to the radiation; clinical diagnosis makes it difficult to make a rapid diagnosis for wounding, so estimating the dose of the irradiation by biological indicators is still not an alternative. The use of biological index analysis to evaluate the biological dose of an irradiated person is currently the most interesting area in radiobiology and radioprotection research.
Although many biological indicators with radiation dose dependence are confirmed by research, the practical application is still less, and more biological dosimeters which are still at the cellular level are applied. Chromosome aberration analysis has been the gold standard for radiation biomass dose estimation, but it is highly demanding on the personal skills and experience of the analyst. The radiation dose estimated by the expression or mutation of a single gene has high randomness, is easily influenced by environmental factors such as smoking and the like, and has large individual difference. There is a need to find new methods that allow scientific and rapid assessment of radiation dose.
Disclosure of Invention
In view of the above-mentioned drawbacks of the prior art, an object of the present invention is to provide a method for estimating a radiation biological dose based on a group of mirnas in peripheral blood plasma, which is used for solving the problems of difficulty in determining the radiation dose and complicated operation in the prior art.
To achieve the above and other related objects, the present invention provides miRNA in peripheral blood plasma of a living body: use of mmu-miR-148a-3p, mma-miR-184-3 p, mma-miR-200 a-5p, mma-miR-218-5 p and mma-miR-375-3 p in calculating radiation dose suffered by organisms.
The organism may be a mammal, such as a human, mouse, or the like. The plasma is derived from peripheral blood of a living body. Peripheral blood should be collected 36h-52h, preferably around 48h, after the organism is exposed to radiation.
In another aspect, the invention provides a method for calculating radiation dose suffered by an organism, wherein the method is characterized by detecting the expression quantity of mmu-miR-148a-3p, mmi-miR-184-3 p, mmi-miR-200 a-5p, mmi-miR-218-5 p and mmi-miR-375-3 p in peripheral blood white blood cells of the organism subjected to radiation for 36-52 h, and substituting the expression quantity into a dose-effect function relation:
D＝0.1733*X miR-130b-5p +0.38*X miR-423-5p +0.3652*X miR-676-3p -0.5728*lg(X miR-150-5p )-0.4806*lg(X miR-342-3p ) -0.6681; wherein D is the irradiation dose, X is the relative expression quantity of each miRNA, and the irradiation dose can be calculated and obtained.
The method for detecting the expression level of miRNA in the peripheral blood of the organism may be any of various methods known in the art, for example, a second-generation sequencing method may be used, or other methods known in the art may be used.
Preferably, the time for obtaining peripheral blood in the method is 48 hours after exposure of the organism to radiation.
Another aspect of the invention provides a product for calculating the radiation dose suffered by an organism, the product comprising the following calculation module:
D＝0.3032*XmiR-148a-3P+0.5144*XmiR-184-3p+0.2406*XmiR-200a-5p+0.1758*XmiR-218-5p+0.5012*XmiR-375-3p-1.105，
wherein D is the irradiation dose, and X is the relative expression amount of each miRNA.
The product can be a microcomputer, and the functional relation is embedded in the microcomputer, so that the radiation dose can be calculated immediately as long as a user inputs the relative expression quantity of each miRNA.
Preferably, the product further comprises a detection reagent for detecting miRNA in peripheral blood.
Preferably, the detection reagent includes, but is not limited to: second generation sequencing detection reagent.
Another aspect of the invention provides a computer storage medium having a computing module as described above.
As described above, the radiation biological dose estimation method based on miRNA in a group of peripheral blood plasma of the present invention has the following beneficial effects:
the method is convenient and quick, is convenient to operate, and can be used for rapidly estimating the radiation dose suffered by the living body.
Detailed Description
Other advantages and effects of the present invention will become apparent to those skilled in the art from the following disclosure, which describes the embodiments of the present invention with reference to specific examples. The invention may be practiced or carried out in other embodiments that depart from the specific details, and the details of the present description may be modified or varied from the spirit and scope of the present invention. It should be understood that the process equipment or devices not specifically identified in the examples below are all conventional in the art.
Brief description of the construction process of the present technical solution:
1) C57BL/6 mice are selected to be divided into 5 groups (0, 2, 4, 6 and 8 Gy) and respectively receive gamma-ray whole body irradiation, peripheral blood of the mice is collected 24 hours after irradiation and 48 hours after irradiation, the change of miRNA expression profile in blood plasma is detected by adopting second generation sequencing, and a group of miRNAs with stable expression level and obvious change are screened out.
We should screen for mirnas that meet the following criteria: a. the radiation sensitivity is high, namely the up-regulation or down-regulation change of the expression quantity before and after irradiation is as large as possible; b. the dependency relationship between the expression quantity and the irradiation dose is stable, namely miRNA expression is definitely dependent on the irradiation dose; mirnas are present in both mice and humans.
In addition, although the basal expression levels of miRNAs in each mouse cannot be completely consistent, the difference is relatively small with respect to the variation thereof, and thus the judgment of the result is not affected.
The more miRNAs are selected, the more accurate the established functional relation is, but the workload of detection is increased. In order to be able to estimate the irradiated radiation dose as soon as possible, considering the above selection criteria, we selected 5 mirnas.
2) And (3) combining the up-regulation or down-regulation times of the miRNA expression quantity of the group relative to the non-irradiation group with the known corresponding irradiation dose, and establishing a dose-effect function relation of the irradiation dose and the up-regulation or down-regulation times of the miRNA expression quantity of the group.
In specific application, the up-regulation or down-regulation times of the miRNA expression amount in the peripheral blood plasma of the mice with unknown irradiation dose are detected, and the irradiation dose can be estimated by taking the miRNA expression amount into the previously established dose-effect function.
The inventor finally determines a group of miRNAs in peripheral blood plasma 48 hours after the selection irradiation through experiments, wherein the total of 5 miRNAs are respectively: mmu-miR-148a-3p, mma-miR-184-3 p, mma-miR-200 a-5p, mma-miR-218-5 p and mma-miR-375-3 p.
Dose-effect function relationships are established according to the expression quantity change multiples of the five miRNAs and the irradiated doses:
D＝0.3032*XmiR-148a-3P+0.5144*XmiR-184-3p+0.2406*XmiR-200a-5p+0.1758*XmiR-218-5p+0.5012*XmiR-375-3p-1.105
wherein D is the irradiation dose, and X is the relative expression amount of each miRNA.
Specific applications of the technical solutions of the present application are described below by means of specific examples.
Example 1 verification of method for estimating the radiation biological dose of miRNA in peripheral blood plasma
To verify the accuracy of the equation we first irradiated the mice with a known dose, then detected the relative expression of the miRNA by experiment, substituted it into the equation to estimate the irradiated dose, and finally the accuracy of the equation estimation was evaluated by comparing the difference between the estimated irradiated dose and the actual irradiated dose. The specific operation is as follows:
1. blood sample collection: taking 1ml of mouse peripheral blood with known irradiation dose, vibrating in an anticoagulation tube for anticoagulation, centrifuging at a low temperature of 4 ℃ by a low-temperature centrifuge at 3000rpm for 10 minutes, and taking 200ul of supernatant plasma; and adding 3ml of erythrocyte lysate into the cell sediment, uniformly blowing and standing for 10 minutes (shaking twice in the middle), centrifuging at 3000rpm for 10 minutes at 4 ℃ by a low-temperature centrifuge, uniformly blowing and washing the sediment by adding 1ml of sterile PBS, centrifuging at 3000rpm for 10 minutes at 4 ℃ by the low-temperature centrifuge to obtain plasma sediment, and re-suspending the plasma sediment to 200ul in volume by PBS.
2. And (3) RNA extraction: extraction of total RNA in the sample is carried out by adopting a MagaBio plus total RNA purification kit BSC53S1E and an NPA-32P nucleic acid purifier matched with the kit. The 96-well plate of the BSC53S1E kit is reversed for 3 times at room temperature, and the plastic packaging film is removed and then the hand is thrown for several times, so that hanging liquid is avoided. The aluminum foil film of the 96-well plate was then torn off and the plate orientation was confirmed. Adding 200ul of ML Buffer into plasma, shaking, mixing, standing for 10 min, transferring into 96-well plate, placing 96-well plate into NPA-32P nucleic acid purifier, installing magnetic bar sheath, and starting automated procedure to extract RNA.
3. RNA concentration determination: the concentration of the extracted total RNA was determined using a Nano Drop nucleic acid meter. After starting the RNA quantification procedure, RNase-free water was used to wash the upper and lower needle tip bases of the instrument, and the experimental absorbent paper was blotted dry. The background was detected by pipetting 2.5ul RNase-free water, then pipetting 2.5ul RNA samples for detection, and recording the sample concentration.
4. Reverse transcription of miRNA: one cDNA synthesized by PolyA tailing can be used to detect multiple miRNAs simultaneously, and the following reaction mixture is added into a 0.2ml RNase-free centrifuge tube in an ice bath: (different kits are slightly different)
| Reagent(s) | Volume (ul) |
| 2×mRQ Buffer | 5 |
| miRNA sample | (0.25-0.8ug) |
| mRQ Enzyme | 1.25 |
| RNase-free H 2 o | Make up 10ul |
| Total volume of | 10ul |
After the centrifugal tube is gently mixed and centrifuged for 3-5 seconds, the mixture is placed in a warm bath at 37 ℃ for 15 minutes, then heated at 85 ℃ for 5 seconds to inactivate enzymes, and then stored at 4 ℃. Add 90ul dd H 2 o constant volume to 100ul. Can be used for the subsequent quantitative PCR detection.
5. Quantitative detection of miRNA: the PCR reaction mixture was prepared on an ice bath with the following components:
| reagent(s) | Volume (ul) |
| dd H 2 o | 9 |
| 2×TB Green Advantage Premix | 12.5 |
| 50×ROX Dye | 0.5 |
| miRNA-specific primer(10uM) | 0.5 |
| mRQ 3’primer(10uM) | 0.5 |
| cDNA | 2 |
| Total volume of | 25ul |
Setting corresponding parameters according to the quantitative PCR instrument
1. Pre-denaturation (1 cycle) at 95℃for 30 seconds
2. PCR reaction (40 cycles)
95 ℃ for 5 seconds
60 ℃ for 34 seconds
3. Dissolution profile (1 cycle)
95 ℃ for 15 seconds
60 ℃ for 60 seconds
95 ℃ for 1 second
The Ct value (Cycle Threshold) was recorded and the relative expression was obtained by the following formula:
relative expression level=2 - [ Ct (target test-housekeeping test) -Ct (target control-housekeeping control)]
6. Calculation of dose estimation: and 3 compound holes are arranged for each sample for detection, the relative expression quantity of each dose point is divided by the relative expression quantity of 0Gy to be used as the up-regulation or down-regulation multiple of the miRNA, the up-regulation multiple and the down-regulation multiple of each miRNA in the fitting curve are substituted into an equation, the estimated value of the irradiated dose can be obtained, the specific experimental results are shown in tables 1-5, and the analysis results are shown in Table 6.
TABLE 1
TABLE 2
TABLE 3 Table 3
TABLE 4 Table 4
TABLE 5
TABLE 6
The smaller the mean square error, the higher the estimation accuracy, and the larger the mean square error, the lower the estimation accuracy. The dose-effect function relationship constructed by the method can be known from Table 6, and compared with the prior art, the method has the advantages of simpler, more convenient and faster operation and more objective result.
The above examples are provided to illustrate the disclosed embodiments of the invention and are not to be construed as limiting the invention. In addition, many modifications and variations of the methods and compositions of the invention set forth herein will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the invention. While the invention has been specifically described in connection with various specific preferred embodiments thereof, it should be understood that the invention should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in the art are intended to be within the scope of the present invention.
Claims (4)
1. A product for detecting plasma in peripheral blood of an organism after the organism has been exposed to radiation for 48 hours for calculating the dose of radiation to which the organism is exposed, characterized in that: the product comprises the following calculation modules: d= 0.3032 ×x miR-148a-3p +0.5144×X miR-184-3p +0.2406×X miR-200a-5p +0.1758 ×X miR-218-5p +0.5012×X miR375-3p -1.105; wherein D is the irradiation dose, and X is the relative expression quantity of each miRNA; wherein the relative expression level of the miRNA is measured by peripheral blood plasma of an organism 48h after the organism is subjected to gamma ray radiation, and the organism is a mouse.
2. The product according to claim 1, characterized in that: the product also comprises a detection reagent for detecting the miRNA in the peripheral blood.
3. The product according to claim 2, characterized in that: the detection reagent comprises: second generation sequencing detection reagent.
4. A computer storage medium, characterized in that the computer storage medium contains the product according to any one of claims 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111636407.XA CN114032294B (en) | 2021-12-29 | 2021-12-29 | Radiation biological dose estimation method based on miRNA in peripheral blood plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111636407.XA CN114032294B (en) | 2021-12-29 | 2021-12-29 | Radiation biological dose estimation method based on miRNA in peripheral blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114032294A CN114032294A (en) | 2022-02-11 |
| CN114032294B true CN114032294B (en) | 2024-02-27 |
Family
ID=80141094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111636407.XA Active CN114032294B (en) | 2021-12-29 | 2021-12-29 | Radiation biological dose estimation method based on miRNA in peripheral blood plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114032294B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103642904A (en) * | 2013-11-20 | 2014-03-19 | 中国人民解放军海军医学研究所 | Application of cyclin G1 as low-dose ionizing radiation biodosimeter |
| WO2016130572A2 (en) * | 2015-02-10 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Methods of determining levels of exposure to radiation and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017070244A1 (en) * | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Biodosimetry analysis |
| US10738363B2 (en) * | 2016-08-31 | 2020-08-11 | National Central University | Analyzer and analytical method for predicting prognosis of cancer radiotherapy |
| JP2020092688A (en) * | 2018-12-12 | 2020-06-18 | 国立大学法人東海国立大学機構 | Body fluid extract containing micro rna |
-
2021
- 2021-12-29 CN CN202111636407.XA patent/CN114032294B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103642904A (en) * | 2013-11-20 | 2014-03-19 | 中国人民解放军海军医学研究所 | Application of cyclin G1 as low-dose ionizing radiation biodosimeter |
| WO2016130572A2 (en) * | 2015-02-10 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Methods of determining levels of exposure to radiation and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| 同剂量γ 射线对人外周血miRNA的表达影响;董娟聪等;中国辐射卫生;第29卷(第5期);第458-461页 * |
| 微小RNA的辐射敏感性和生物标记作用的研究进展;栗贺等;现代药物与临床;第36卷(第9期);第1976-1982页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114032294A (en) | 2022-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105349654B (en) | A kind of probe for detecting EGFR genetic mutation, primer, detection architecture and kit | |
| CN102369294A (en) | Non-small cell lung cancer detection marker, detection method thereof, related reagent kit and biochip | |
| CN101988120A (en) | Novel technology for diagnosing liver cancer by utilizing microRNAs in serum | |
| CN110295229A (en) | Application of the PRDM1 as marker in preparation diagnostic activities product lungy | |
| CN109295218A (en) | Circular rna marker hsa_circ_0001788 and its application | |
| CN107338324A (en) | For the serum lncRNA marks of acatalepsia reason recurrent miscarriage, primer sets and application and kit | |
| CN105112544A (en) | Probes, primers and kit for detecting T790M mutation of EGFR gene | |
| CN103773896B (en) | The fluorescence quantitative RT-PCR detecting agent of west nile virus, test kit and detection method thereof | |
| CN105821143A (en) | Primer and method for detecting hypertension-susceptibility-related SNP site | |
| CN109385472A (en) | A kind of serum miRNA marker and its method for detecting ionization radiation injury | |
| CN112501301A (en) | Primer and probe combination for quantitatively detecting BCR-ABL fusion gene, kit and using method thereof | |
| CN114032294B (en) | Radiation biological dose estimation method based on miRNA in peripheral blood plasma | |
| CN111218504A (en) | Application of hsa-miR-320d as molecular marker for radiation exposure diagnosis | |
| CN114277159B (en) | Radiation biological dose estimation method based on miRNA in group of peripheral blood leucocytes | |
| CN104694623A (en) | Plasma miRNA marker for diagnosis of lung cancer and application | |
| CN109652510A (en) | Detect primer, probe and the method and kit of BAALC gene relative expression quantity in sample | |
| CN108300788A (en) | A kind of micro RNA combination and its application for detecting light-duty brain trauma | |
| CN107904303A (en) | For detecting the primer sets of 140 3p of biliary atresia children blood plasma miR and detection kit comprising the primer sets | |
| CN114277122A (en) | Application of peripheral blood leukocyte miR-150-5p in calculating radiation dose | |
| CN114231614A (en) | Application of miR-342-3p in peripheral blood leukocytes in calculating radiation dose | |
| CN115058510A (en) | Application of miR-130b-5p in peripheral blood leukocytes in calculating radiation dose | |
| WO2022156610A1 (en) | Prediction tool for determining sensitivity of liver cancer to drug and long-term prognosis of liver cancer on basis of genetic testing, and application thereof | |
| CN110241199A (en) | MiR-584-5p is as the application in acute respiratory distress syndrome biomarker | |
| Yang et al. | Transcriptome analysis of cold syndrome using microarray | |
| CN110373457A (en) | A kind of mRNA marker and its application for ulcerative colitis diagnosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |